May 25, 2022
View Full PaperGliflozins in the Management of Cardiovascular Disease
Key Points
Key points are not available for this paper at this time.
Abstract
Gliflozins — sodium–glucose cotransporter 2 inhibitors — lower blood glucose and glycated hemoglobin in patients with type 2 diabetes without causing hypoglycemia. The agents also improve cardiac function in patients who have heart failure with or without type 2 diabetes and improve renal function, with few adverse effects.